NanoViricides, Inc. (NYSE American: NNVC) is advancing its investigational broad-spectrum antiviral drug NV-387 toward Phase II clinical trials for the treatment of measles, the company announced. The move comes as measles cases are rising in the United States and internationally, underscoring an unmet medical need for effective therapies against the highly contagious virus.
The company is developing a clinical trial protocol for submission to the U.S. Food and Drug Administration through an Investigational New Drug process. NV-387 has already demonstrated antiviral activity against measles in a humanized mouse model and completed a juvenile mouse toxicity study in which no treatment-related adverse effects were observed at the highest dose tested. The drug has also completed a Phase I human safety study and is currently being evaluated in separate Phase II trials for Ebola Bundibugyo virus and mpox in the Democratic Republic of Congo.
NV-387 has received both Orphan Drug Designation and Rare Pediatric Disease Drug (RPDD) Designation from the FDA for measles treatment. The RPDD designation could make NanoViricides eligible for a Priority Review Voucher following approval of a qualifying marketing application, subject to applicable requirements. Such a voucher can be sold or used to expedite regulatory review of a future product, potentially adding significant value for the company.
The advancement of NV-387 matters beyond NanoViricides because measles remains a serious global health threat, particularly for children in regions with low vaccination coverage. The company said its development program addresses an unmet medical need amid rising measles cases. However, NV-387 remains investigational and has not been approved for treating measles or any other viral disease. Investors can find more details in the full press release at https://ibn.fm/lWeDl and stay updated on NNVC developments through the company’s newsroom at https://ibn.fm/NNVC.
NanoViricides is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. The company’s other advanced candidate is NV-HHV-1 for shingles. NanoViricides’ business model is based on licensing technology from TheraCour Pharma, Inc. for specific application verticals of specific viruses. The company holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Ebola/Marburg, and certain Coronaviruses.
For more information about NanoViricides, visit www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. This news is distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
